All posts by GTCbio


Ocular Diseases Drug Discovery

GTCbio | November 29th, 2017

By 2050, it is projected that vision loss will grow to affect more than 10 million people, from the current statistic of 4.4 million. The total prevalence of cataract, diabetic retinopathy, glaucoma and AMD is expected to increase to nearly 70 million adults by 2050 which urges to development of drugs for ocular diseases. In…read more

Human vs Technology or Human with Technology – What’s better?

Satish Medicetty | November 15th, 2017

This continues to be an interesting question, and I approached it with a different perspective from a recent experience. I just got back from the Society for Neuroscience (SFN) 49th Annual Meeting, which had almost 30,000 attendees. I have been at this meeting many times in the past and yet I am surprised by the…read more

Enzymes in Drug Discovery Summit

GTCbio | November 7th, 2017

Enzymes have historically been considered attractive drug targets for therapeutics because of their specificity and susceptibility to drug modulation. More than 250 genes coding for enzymes, have been identified as FDA-approved drug targets and this further highlights the continued importance of investigating enzyme targets. Therefore, with the rise in demand for effective therapeutic agents, the…read more